Share your videos with the world

Sign Up | Log In | Help  
   
 
Most Discussed Basic View | Detailed View Videos 13705-13716 of 28927
 
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Added: 4425 days ago by MultiVuVideos
Runtime: 2m13s
Views: 1029 | Comments: 0
Today Concentrix Corporation, a wholly-owned subsidiary of SYNNEX Corporation (NYSE: SNX), announced the addition of 19 delivery locations, across 13 countries, completing the second phase of the acquisition of IBM's global customer care and industry process services business. With over 95% of the acquisition completed, Concentrix continues to advance its position as a leader in the customer care and industry process services market, with over 45,000 employees delivering high value services. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7146451-concentrix-completes-2nd-phase-of-ibm-customer-care-business-acquisition
Added: 4425 days ago by MultiVuVideos
Runtime: 1m52s
Views: 1771 | Comments: 0
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Added: 4425 days ago by MultiVuVideos
Runtime: 6m10s
Views: 1688 | Comments: 0
John Hagee
Added: 2203 days ago by DivineRevelations
Runtime: 3m44s
Views: 1461 | Comments: 1
     
The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
Added: 4414 days ago by MultiVuVideos
Runtime: 4m43s
Views: 1017 | Comments: 0
The Names of God
Added: 2203 days ago by DivineRevelations
Runtime: 9m58s
Views: 1137 | Comments: 1
     
Don't you know your in a fight? Inspirational, Educational, and Motivational
Added: 2203 days ago by DivineRevelations
Runtime: 2m46s
Views: 1009 | Comments: 1
     
http://www.myrainbowbridge.co/How much is saving a dog's life worth to you? Now you can make a true difference in the world by helping give an unwanted dog a home, a place to call his own without kennels or cages and win a trip to Hawaii all at the same time. Rainbow Bridge is a true dog sanctuary where we want to give all the homeless and unwanted dogs of San Diego a place to call their own. Donate now at our website and be entered into our Hawaii trip giveaway. www.MyRainbowBridge.co‎‎
Added: 4421 days ago by johngeltkn
Runtime: 1m38s
Views: 1288 | Comments: 1
Car stuck in reverse.
Added: 4417 days ago by Orthrus
Runtime: 1m8s
Views: 1715 | Comments: 0
American designer Sigrid Olsen announces reacquisition of rights to her namesake (“Sigrid Olsen”) brand this May. With success as a multi-million dollar national women’s fashion and lifestyle business, Sigrid revitalizes business potential focused on a unique vision of mindful design, beautiful products, and holistic experiences, with a unique commitment to creative well-being, nature, balance, simplicity and joy. Establishing a select team based between New York and Florida, she sets new sights on the creation of a coastal creative headquarters in Sarasota and opens her next chapter celebrating 30 years, combined, as an independent artist, creative entrepreneur, American fashion and home designer, and healthy wellbeing advocate and global retreat leader. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7142231-sigrid-olsen-new-designs-for-living/
Added: 4420 days ago by MultiVuVideos
Runtime: 2m53s
Views: 1386 | Comments: 1
Valvoline SynPower TVC - visit http://www.synpower.com.au/ for product information.‎‎
Added: 4420 days ago by johngeltkn
Runtime: 1m0s
Views: 758 | Comments: 0
Concur (Nasdaq: CNQR), the leading provider of spend management solutions and services in the world, today kicks off Fusion, its premier client event of the year, at The New Orleans Ernest N. Morial Convention Center. A special opening day keynote by the company’s founders showcased the future of integrated business travel and expenses and urged the entire industry to think about their own perfect trip and the evolving ecosystem required to support it. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7203651-concur-kicks-off-fusion-2014-collaborate-fast-growing-open-platform
Added: 4404 days ago by MultiVuVideos
Runtime: 3m19s
Views: 935 | Comments: 0
[First Page] [Previous Page]   1139  1140  1141  1142  1143  1144  1145  1146  1147  1148  1149  1150  1151  1152   [Next Page] [Last Page]
  2411  Pages Total  
PHP Scripts and Service

About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2026 ClipMoon.com. All rights reserved.